((自动化翻译由路透提供,请见免责声明 ))
路透9月12日 - Fulcrum Therapeutics 周四称,该公司用于治疗一种遗传性肌肉疾病的实验性药物未能在一项后期研究中达到主要目标。
在盘前交易中,该公司股价下跌超过70%,至2.4美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.